Literature DB >> 8816144

Granulomatous infections: etiology and classification.

A Zumla1, D G James.   

Abstract

Granulomatous disorders are frequently due to a wide variety of infections. Over the past decade advances in molecular diagnostic techniques have allowed identification of organisms involved in granulomatous disorders that previously were of unknown etiology. On the basis of currently available information, granulomatous infections can now be classified in three categories. Group 1 infections are due to a well-recognized organism. Group 2 comprises infections due to organisms that have been recently identified in granulomas by molecular methods but are not readily isolated by conventional microbiological techniques. Group 3 consists of disorders for which the causal organisms have not yet been identified but are strongly suspected; further advances in diagnostic techniques will lead to reclassification of some of these disorders as group 2. This review describes the etiology, histopathologic features, and classification of granulomatous disorders, with an emphasis on those of groups 2 and 3.

Entities:  

Mesh:

Year:  1996        PMID: 8816144     DOI: 10.1093/clinids/23.1.146

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  Immune modulators in disease: integrating knowledge from the biomedical literature and gene expression.

Authors:  Nophar Geifman; Sanchita Bhattacharya; Atul J Butte
Journal:  J Am Med Inform Assoc       Date:  2015-12-11       Impact factor: 4.497

2.  An Expandable Mechanopharmaceutical Device (2): Drug Induced Granulomas Maximize the Cargo Sequestering Capacity of Macrophages in the Liver.

Authors:  Phillip Rzeczycki; Gi Sang Yoon; Rahul K Keswani; Sudha Sud; Jason Baik; Mikhail D Murashov; Ingrid L Bergin; Kathleen A Stringer; Gus R Rosania
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

Review 3.  A clinicopathological classification of granulomatous disorders.

Authors:  D G James
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

Review 4.  Eosinophils and Macrophages within the Th2-Induced Granuloma: Balancing Killing and Healing in a Tight Space.

Authors:  Anupama Ariyaratne; Constance A M Finney
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

5.  HtrA stress protein is involved in intramacrophagic replication of adherent and invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease.

Authors:  Marie-Agnès Bringer; Nicolas Barnich; Anne-Lise Glasser; Olivier Bardot; Arlette Darfeuille-Michaud
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death.

Authors:  A L Glasser; J Boudeau; N Barnich; M H Perruchot; J F Colombel; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 7.  Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

Authors:  Daniel Smyk; Eirini I Rigopoulou; Yoh Zen; Robin Daniel Abeles; Charalambos Billinis; Albert Pares; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

8.  The oxidoreductase DsbA plays a key role in the ability of the Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 to resist macrophage killing.

Authors:  Marie-Agnès Bringer; Nathalie Rolhion; Anne-Lise Glasser; Arlette Darfeuille-Michaud
Journal:  J Bacteriol       Date:  2007-04-20       Impact factor: 3.490

Review 9.  Liver immunology.

Authors:  Dimitrios P Bogdanos; Bin Gao; M Eric Gershwin
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 10.  Granulomas in parasitic diseases: the good and the bad.

Authors:  Selma Giorgio; Pedro Henrique Gallo-Francisco; Guilherme Augusto Sanches Roque; Marina Flóro E Silva
Journal:  Parasitol Res       Date:  2020-08-13       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.